Glenmark Pharmaceuticals has gained 2.4 per cent.
CLSA has given it a "buy" rating and a target price of Rs 1,060.
It says the drugmaker is at the cusp of a revival with a pick-up in US approvals.
The stock has 24 "buys", six "holds" and one "sell" rating.